Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency

Immunoglobulin (Ig)-replacement therapy represents the mainstay of treatment for patients with primary antibody deficiency and is administered either intravenously (IVIg) or subcutaneously (SCIg). While hyaluronidase has been used in clinical practice for over 50 years, the development of a high-pur...

Descripción completa

Detalles Bibliográficos
Autor principal: Jolles, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928364/
https://www.ncbi.nlm.nih.gov/pubmed/27471693
http://dx.doi.org/10.2147/ITT.S31136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928364/
https://www.ncbi.nlm.nih.gov/pubmed/27471693
http://dx.doi.org/10.2147/ITT.S31136

Ejemplares similares